.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,141,593

« Back to Dashboard

Claims for Patent: 7,141,593

Title:Pharmaceutical formulations
Abstract:Improved pharmaceutical compositions are provided comprising one or more solubilized HIV protease inhibiting compounds having improved solubility properties in a medium and/or long chain fatty acid, or mixtures thereof, a pharmaceutically acceptable alcohol, and water.
Inventor(s): Alani; Laman (Morris Plains, NJ), Ghosh; Soumojeet (Linderhurst, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:09/576,097
Patent Claims: 1. A pharmaceutical composition comprising a solution which comprises: (a) (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)ami- no)carbonyl)-L-valinyl)amino)-2-(N-((5thiazolyl)methoxy-carbonyl)-amino)-1- ,6-diphenyl-3-hydroxyhexane (ritonavir) or a combination of ritonavir and another HIV protease inhibiting compound, or pharmaceutically acceptable salts thereof, in an amount of from 1% to 50% by weight of said solution; (b) a pharmaceutically acceptable medium and/or long chain fatty acid, or a mixture of pharmaceutically acceptable medium and/or long chain fatty acids, in an amount of from 30% to 75% by weight of said solution; (c) ethanol or propylene glycol in an amount of from 1% to 15% by weight of said solution; (d) water in an amount of from 0.4% to 3.5% by weight of said solution; and, optionally, (e) a pharmaceutically acceptable surfactant.

2. The composition according to claim 1, wherein said solution comprises ritonavir and said another HIV protease inhibiting compound.

3. The composition according to claim 2, wherein said another HIV protease inhibiting compound is (2S,3 S,5S)-2-(2,6-dimethylphenoxyacetyl)-amino-3-hydroxy-5-(2S-(1-tetrahydropy- rimid-2-onyl)-3-methyl-butanoyl)amino-1,6-diphenylhexane (ABT-378).

4. The composition according to claim 2, wherein said another HIV protease inhibiting compound is a compound selected from the group consisting of: (1) (2S,3S,5 S)-2-(2,6-dimethylphenoxyacetyl)-amino-3-hydroxy-5-(2S-(1-tetrahydropyrim- id-2-onyl)-3-methyl-butanoyl)amino-1,6-diphenylhexane, (2) N-(2(R)-hydroxy-1 (S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S- )-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide (indinavir), (3) N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbo- nyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3 (S)-carboxamide (saquinavir), (4) 5(S)-Boc-amino-4(S)-hydroxy-6-phenyl-2(R)-phenylmethylhexanoyl-(L)-Val-(L- )-Phe-morpholin-4-ylamide, (5) 1-Naphthoxyacetyl-beta-methylthio-Ala-(2S, 3S)-3-amino-2-hydroxy-4-butanoyl 1,3-thiazolidine-4-t-butylamide, (6) 5-isoquinolinoxyacetyl-beta-methylthio-Ala-(2S,3 S)-3-amino-2-hydroxy-4-butanoyl-1,3-thiazolidine-4-t-butylamide, (7) [1S-[1R-(R-),2S*])--N.sup.1 [3-[[[(1,1-dimethylethyl)amino]carbonyl](2-methylpropyl) amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-- butanediamide, (8) ##STR00011## ##STR00012## or a pharmaceutically acceptable salt thereof.

5. The composition according to claim 1, wherein said surfactant is in an amount of from 2% to 20% by weight of said solution.

6. The composition according to claim 1, wherein said solution comprises ritonavir or a combination of ritonavir and said another HIV protease inhibiting compound, or pharmaceutically acceptable salts thereof, in an amount of from 10 to 40% by weight of said solution.

7. The composition according to claim 1, wherein said solution comprises a pharmaceutically acceptable organic solvent in an amount of from 50% to 75% by weight of said solution, and said solvent includes: (a) a pharmaceutically acceptable medium and/or long chain fatty acid, or a mixture of pharmaceutically acceptable medium and/or long chain fatty acids, in an amount of from 30% to 75% by weight of said solution; and (c) ethanol or propylene glycol in an amount of from 1% to 15% by weight of said solution.

8. The composition of claim 1, wherein said solution comprises water in an amount of from 0.4% to 1.5% by weight of said solution.

9. The composition according to claim 1, wherein said solution comprises oleic acid in an amount of from 30% to 75% by weight of said solution.

10. The composition according to claim 1, wherein said surfactant is polyoxyl 35 castor oil.

11. The composition according to claim 1, wherein said solution comprises: (a) ritonavir in an amount from 1% to 30% by weight of said solution; (b) a pharmaceutically acceptable medium and/or long chain fatty acid in an amount of from 30% to 75% by weight of said solution; (c) ethanol in an amount of from 1% to 15% by weight of said solution; (d) water in an amount of from 0.4% to 3.5% by weight of said solution; and (e) polyoxyl 35 castor oil in an amount of from 0% to 20% by weight of said solution.

12. The composition of claim 1, wherein said solution comprises: (a) a combination of ritonavir and (2S, 3S, 5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydropyrim- id-2-onyl)-3-methylbutanoyl]-amino-1,6-diphenylhexane, in an amount of from 1% to 45% by weight of said solution; (b) a pharmaceutically acceptable medium and/or long chain fatty acid in an amount of from 30% to 75% by weight of said solution; (c) propylene glycol in an amount of from 1% to 15% by weight of said solution; (d) water in an amount of from 0.4% to 3.5% by weight of said solution; and (e) polyoxyl 35 castor oil in an amount of from 0% to 20% by weight of said solution.

13. The composition according to claim 1, wherein said solution comprises: (a) ritonavir in an amount from 1% to 30% by weight of said solution; (b) oleic acid in an amount of from 30% to 75% by weight of said solution; (c) ethanol in an amount of from 1% to 15% by weight of said solution; (d) water in an amount of from 0.4% to 3.5% by weight of said solution; and (e) polyoxyl 35 castor oil in an amount of from 0% to 20% by weight of said solution.

14. The composition according to claim 13, wherein said solution comprises: (a) ethanol in an amount of from 3% to 12% by weight of said solution; and (b) polyoxyl 35 castor oil in an amount of from 2.5% to 10% by weight of said solution.

15. The composition of claim 1, wherein said solution comprises: (a) ritonavir in an amount of 10% by weight of said solution; (b) oleic acid in an amount of from 70% to 75% by weight of said solution; (c) ethanol in an amount of from 3% to 12% by weight of said solution; (d) water in an amount of from 0.4% to 1.5% by weight of said solution; and (e) polyoxyl 35 castor oil in an amount of 6% by weight of said solution.

16. The composition of claim 1, wherein said solution comprises: (a) a combination of ritonavir and (2S, 3S, 5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydropyrim- id-2-onyl)-3-methylbutanoyl]-amino-1,6-diphenylhexane, in an amount of from 1% to 45% by weight of said solution; (b) oleic acid in an amount of from 30% to 75% by weight of said solution; (c) propylene glycol in an amount of from 1% to 8% by weight of said solution; (d) water in an amount of from 0.4% to 3.5% by weight of said solution; and (e) polyoxyl 35 castor oil in an amount of from 0% to 20% by weight of said solution.

17. The composition of claim 1, wherein said solution comprises: (a) a combination of ritonavir and (2S, 3S, 5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydropyrim- id-2-onyl)-3-methylbutanoyl]-amino-1,6-diphenylhexane, in an amount of 10% by weight of said solution; (b) oleic acid in an amount of from 70% to 75% by weight of said solution; (c) propylene glycol in an amount of from 1% to 15% by weight of said solution; (d) water in an amount of from 0.4% to 1.5% by weight of said solution; and (e) polyoxyl 35 castor oil in an amount of 6% by weight of said solution.

18. The composition according to claim 1, further comprising a hard or soft elastic gelatin capsule which encapsulates said solution.

19. The composition according to claim 3, further comprising a hard or soft elastic gelatin capsule which encapsulates said solution.

20. The composition according to claim 9, further comprising a hard or soft elastic gelatin capsule which encapsulates said solution.

21. The composition according to claim 11, further comprising a hard or soft elastic gelatin capsule which encapsulates said solution.

22. The composition according to claim 12, further comprising a hard or soft elastic gelatin capsule which encapsulates said solution.

23. The composition according to claim 13, further comprising a hard or soft elastic gelatin capsule which encapsulates said solution.

24. The composition according to claim 15, further comprising a hard or soft elastic gelatin capsule which encapsulates said solution.

25. The composition according to claim 16, further comprising a hard or soft elastic gelatin capsule which encapsulates said solution.

26. The composition according to claim 17, further comprising a hard or soft elastic gelatin capsule which encapsulates said solution.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc